UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number 001-39614 TARSUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 81-4717861 (State or other ju ...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Conference Call February 27, 2024 8:00 AM ET Company Participants Bobby Azamian - Chairman, CEO Jeff Farrow - CFO, CSO Aziz Mottiwala - CCO Sesha Neervannan - COO David Nakasone - Head, IR Conference Call Participants François Brisebois - Oppenheimer Jason Gerberry - Bank of America Oren Livnat - H.C. Wainwright Balaji Prasad - Barclays Corey Jubinville - Life Sci Capital Eddie Hickman - Guggenheim Securities Tim Lugo - William Blair Operator Good ...

Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements Launched XDEMVY (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and generated fourth quarter net product sales of $13.1 million, and $14.7 million in the first four months since launch ® Delivered more than 17,400 bottles of XDEMVY to patients Continued pipeline execution – reported positive proof-of-concept results across entire clinical portfolio Management to host con ...

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants David Nakasone - Head, IR Bobak Azamian - Chairman, CEO Aziz Mottiwala - CCO Jeff Farrow - CFO, CSO Conference Call Participants Jason Gerberry - Bank of America Eddie Hickman - Guggenheim Securities Oren Livnat - H.C. Wainwright Frank Brisebois - Oppenheimer Operator Good afternoon and welcome to the Tarsus Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. As a rem ...

Table of Contents ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ____ . Commission File Number: 001-39614 TARSUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 81-4717861 (State or other jurisdiction of incorporation or organization) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCH ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ____ . Commission File Number: 001-39614 TARSUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 81-471786 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ____ . Commission File Number: 001-39614 TARSUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 81-47178 ...

TP-03 Vehicle 20 23 © Tarsus Pharmaceuticals Active Disease Education Building Purposeful Momentum Toward Launch Early and frequent disease education, market awareness & engagement activities to prepare market confident diagnosis 1 st all optometrist field medical team • ECPs excited about compelling value proposition and the opportunity to potentially provide a solution to patients and expand/optimize their practice • Positive initial payer feedback from top commercial and Medicare accounts may enable acce ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number 001-396147 TARSUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 81-4717861 (State or other j ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ____ . Commission File Number: 001-39614 TARSUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 81-4 ...